

Title (en)
FUSION PROTEINS FOR THE TREATMENT OF CNS

Title (de)
FUSIONSPROTEINE ZUR BEHANDLUNG DES ZNS

Title (fr)
PROTEINES DE FUSION DESTINEES AU TRAITEMENT DU SYSTEME NERVEUX CENTRAL

Publication
EP 1646353 A4 20080604 (EN)

Application
EP 04776038 A 20040517

Priority
• US 2004015661 W 20040517
• US 47130003 P 20030516
• US 47123603 P 20030516
• US 47123903 P 20030516
• US 47437203 P 20030529
• US 47124003 P 20030516

Abstract (en)
[origin: WO2004110359A2] This disclosure relates to compositions capable of use in the treatment of spinal cord injuries and related disorders of the central nervous system (CNS), and in particular, compositions including proteoglycan degrading molecules and compositions capable of blocking and/or over coming the activity of neuronal growth inhibitory molecules, as well as fusion proteins which includes a proteoglycan degrading domain and a domain capable of blocking and or over coming the activity of neuronal growth inhibitory molecules.

IPC 8 full level
C12P 21/06 (2006.01); **A61K 31/00** (2006.01); **A61K 38/51** (2006.01); **C07K 14/475** (2006.01); **C12N 9/88** (2006.01)

IPC 8 main group level
A61K (2006.01)

CPC (source: EP)
A61K 38/51 (2013.01); **A61P 9/00** (2017.12); **A61P 17/02** (2017.12); **A61P 25/00** (2017.12); **A61P 25/16** (2017.12); **A61P 25/28** (2017.12); **A61P 43/00** (2017.12); **C07K 14/4756** (2013.01); **C12N 9/88** (2013.01); **C07K 2319/10** (2013.01)

Citation (search report)
• [X] WO 02055684 A2 20020718 - UNIV IOWA RES FOUND [US], et al
• [X] WO 02083179 A2 20021024 - BIOAXONE THERAPEUTIQUE INC [CA]
• [Y] WO 0062067 A1 20001019 - UNIV WASHINGTON [US]
• [PX] WO 2004017044 A2 20040226 - ACORDA THERAPEUTICS INC [US], et al
• [X] US 6171575 B1 20010109 - OKUYAMA SHINICHI [JP]
• [PX] WO 03100031 A2 20031204 - UNIV TEXAS [US], et al
• [Y] MCGEE A W ET AL: "The Nogo-66 receptor: focusing myelin inhibition of axon regeneration", TRENDS IN NEUROSCIENCE, ELSEVIER, AMSTERDAM, NL, vol. 26, no. 4, April 2003 (2003-04-01), pages 193 - 198, XP004418152, ISSN: 0166-2236
• [Y] BRADBURY E J ET AL: "Chondroitinase ABC promotes functional recovery after spinal cord injury", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 416, 11 April 2002 (2002-04-11), pages 636 - 640, XP002245003, ISSN: 0028-0836
• See references of WO 2004110359A2

Citation (examination)
• FROM WIKIPEDIA: "Route of administration", 5 January 2016 (2016-01-05), XP055243671
• "ROUTE OF ADMINISTRATION - FDA", 11 January 2006 (2006-01-11), XP055243674

Cited by
US8906363B2; US9528102B2; US8226941B2; US8404232B2; US9102930B2; US9410141B2; US9987340B2; US8236302B2; US9402886B2; US9834764B2; US10323240B2; US7959914B2; US8183350B2; US8679481B2; US8785606B2; US9468671B2; US9839679B2; US9956273B2; US11141467B2

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)
AL HR LT LV MK

DOCDB simple family (publication)
WO 2004110359 A2 20041223; WO 2004110359 A3 20060817; WO 2004110359 A9 20060216; AU 2004247025 A1 20041223; AU 2004247025 B2 20110623; AU 2004247025 B8 20110630; CA 2525782 A1 20041223; CA 2525782 C 20190205; EP 1646353 A2 20060419; EP 1646353 A4 20080604; EP 2354155 A2 20110810; EP 2354155 A3 20110907; EP 2354155 B1 20170503; EP 3210999 A1 20170830; EP 3210999 B1 20200826; ES 2831031 T3 20210607; JP 2007516229 A 20070621; JP 2013049677 A 20130314; JP 2014221793 A 20141127; JP 2017125035 A 20170720; JP 2020111578 A 20200727; JP 5399612 B2 20140129; JP 5656314 B2 20150121; JP 6141571 B2 20170712; JP 6913428 B2 20210804; MX 351062 B 20170929; MX PA05012306 A 20060418

DOCDB simple family (application)
US 2004015661 W 20040517; AU 2004247025 A 20040517; CA 2525782 A 20040517; EP 04776038 A 20040517; EP 10184697 A 20040517; EP 17164945 A 20040517; ES 17164945 T 20040517; JP 2006533212 A 20040517; JP 2012215041 A 20120927; JP 2014138911 A 20140704; JP 2017030467 A 20170221; JP 2020034479 A 20200229; MX 2012003710 A 20040517; MX PA05012306 A 20040517